vorinostat and Hemorrhagic Thrombocythemia studies

vorinostat and Hemorrhagic Thrombocythemia

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

Excerpt	Relevance	Reference
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients."	9.19	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014)
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients."	5.19	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014)
"Treatment with vorinostat resulted in a younger MA in PV patients and older MA in ET patients, in both cases a trend towards the normal chronological age."	2.90	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. ( Andersen, C; Greenfield, G; Grinfeld, J; Hasselbalch, HC; McMullin, MF; McPherson, S; Mills, KI; Nangalia, J, 2019)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

1 (25.00)

29.6817

2010's

3 (75.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
McPherson, S	1
Greenfield, G	1
Andersen, C	1
Grinfeld, J	1
Hasselbalch, HC	3
Nangalia, J	1
Mills, KI	1
McMullin, MF	3
Andersen, CL	2
Ejerblad, E	2
Zweegman, S	2
Harrison, C	2
Fernandes, S	2
Bareford, D	2
Knapper, S	2
Samuelsson, J	2
Löfvenberg, E	2
Linder, O	2
Andreasson, B	2
Ahlstrand, E	2
Jensen, MK	2
Bjerrum, OW	2
Vestergaard, H	2
Larsen, H	2
Klausen, TW	2
Mourits-Andersen, T	2
Bjørn, ME	1
Skov, V	1
Thomassen, M	1
Kruse, T	1
Grønbæk, K	1
Lee, J	1

Studies

McPherson, S

Greenfield, G

Andersen, C

Grinfeld, J

Hasselbalch, HC

Nangalia, J

Mills, KI

McMullin, MF

Andersen, CL

Ejerblad, E

Zweegman, S

Harrison, C

Fernandes, S

Bareford, D

Knapper, S

Samuelsson, J

Löfvenberg, E

Linder, O

Andreasson, B

Ahlstrand, E

Jensen, MK

Bjerrum, OW

Vestergaard, H

Larsen, H

Klausen, TW

Mourits-Andersen, T

Bjørn, ME

Skov, V

Thomassen, M

Kruse, T

Grønbæk, K

Lee, J

Trials

3 trials available for vorinostat and Hemorrhagic Thrombocythemia

Article	Year
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental hematology, 2019, Volume: 79 Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Epigenesis, Geneti	2019
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British journal of haematology, 2013, Volume: 162, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic	2013
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia research, 2014, Volume: 38, Issue:7 Topics: Adipokines; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Chitinase-3-Like Protein 1; Female;	2014

Article

Year

Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.

Experimental hematology, 2019, Volume: 79

Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Epigenesis, Geneti

2019

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

British journal of haematology, 2013, Volume: 162, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic

2013

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Leukemia research, 2014, Volume: 38, Issue:7

Topics: Adipokines; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Chitinase-3-Like Protein 1; Female;

2014

Other Studies

1 other study available for vorinostat and Hemorrhagic Thrombocythemia

Article	Year
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Annals of hematology, 2009, Volume: 88, Issue:7 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd	2009

Article

Year

Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.

Annals of hematology, 2009, Volume: 88, Issue:7

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd

2009